Millennium Management LLC Reports 3.7% Stake in KalVista Pharmaceuticals, Inc. (KALV)

On May 1, 2026, Millennium Management LLC and associated reporting persons, including Israel A. Englander, filed a Schedule 13G/A regarding their holdings in KalVista Pharmaceuticals, Inc. (KALV). The filing indicates that as of the event date on March 31, 2026, the reporting group collectively held 1,912,146 shares of common stock, representing a 3.7% ownership stake in the company. This reflects an increase from a previously reported 0% position, though the total ownership remains below the 5% threshold typically requiring a Schedule 13D. The reporting entities include Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. The securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and its managing member. The filing was made under Rule 13d-1(c), certifying that the shares were not acquired for the purpose of changing or influencing the control of the issuer.